Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued
Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...
Earnings call transcript: ResMed surpasses Q2 FY2025 expectations, stock dips
ResMed Inc . (NYSE:RMD) reported its financial results for the second quarter of fiscal year 2025, exceeding analysts' expectations with an earnings per share (EPS) of $2.43, surpassing the forecasted ...
This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry
This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy ...
Nvidia’s Jensen Huang sells $14 million in stock almost daily—raising questions about his successor
Five years ago Nvidia CEO Jensen Huang was worth a respectable $3.73 billion. At the time of writing ... t look good' Huang ...